287 related articles for article (PubMed ID: 26302836)
21. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
22. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
23. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
24. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.
Jamous M; Tamma ML; Gourni E; Waser B; Reubi JC; Maecke HR; Mansi R
Nucl Med Biol; 2014 Jul; 41(6):464-70. PubMed ID: 24780298
[TBL] [Abstract][Full Text] [Related]
25. 1,2,3-Triazole Stabilized Neurotensin-Based Radiopeptidomimetics for Improved Tumor Targeting.
Mascarin A; Valverde IE; Vomstein S; Mindt TL
Bioconjug Chem; 2015 Oct; 26(10):2143-52. PubMed ID: 26347939
[TBL] [Abstract][Full Text] [Related]
26. Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
Janssen PJ; de Visser M; Verwijnen SM; Bernard BF; Srinivasan A; Erion JL; Breeman WA; Vulto AG; Krenning EP; de Jong M
Cancer Biother Radiopharm; 2007 Jun; 22(3):374-81. PubMed ID: 17651043
[TBL] [Abstract][Full Text] [Related]
27. Structure-Activity Relationship Studies of Amino Acid Substitutions in Radiolabeled Neurotensin Conjugates.
Mascarin A; Valverde IE; Mindt TL
ChemMedChem; 2016 Jan; 11(1):102-7. PubMed ID: 26593062
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors.
García-Garayoa E; Allemann-Tannahill L; Bläuenstein P; Willmann M; Carrel-Rémy N; Tourwé D; Iterbeke K; Conrath P; Schubiger PA
Nucl Med Biol; 2001 Jan; 28(1):75-84. PubMed ID: 11182567
[TBL] [Abstract][Full Text] [Related]
29. Improved radiosynthesis and preliminary in vivo evaluation of a (18)F-labeled glycopeptide-peptoid hybrid for PET imaging of neurotensin receptor 2.
Maschauer S; Greff C; Einsiedel J; Ott J; Tripal P; Hübner H; Gmeiner P; Prante O
Bioorg Med Chem; 2015 Jul; 23(14):4026-33. PubMed ID: 25691211
[TBL] [Abstract][Full Text] [Related]
30. Neurotensin negatively modulates Akt activity in neurotensin receptor-1-transfected AV12 cells.
Liu F; Yang P; Baez M; Ni B
J Cell Biochem; 2004 Jun; 92(3):603-11. PubMed ID: 15156571
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation of NHS-Activated Gold Nanoparticles Functionalized with Bombesin or Neurotensin-Like Peptides for Targeting Colon and Prostate Tumours.
Chilug LE; Niculae D; Leonte RA; Nan A; Turcu R; Mustaciosu C; Serban RM; Lavric V; Manda G
Molecules; 2020 Jul; 25(15):. PubMed ID: 32722221
[TBL] [Abstract][Full Text] [Related]
32. (18)F- and (68)Ga-Labeled Neurotensin Peptides for PET Imaging of Neurotensin Receptor 1.
Maschauer S; Einsiedel J; Hübner H; Gmeiner P; Prante O
J Med Chem; 2016 Jul; 59(13):6480-92. PubMed ID: 27336295
[TBL] [Abstract][Full Text] [Related]
33. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
34. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation.
Brun P; Mastrotto C; Beggiao E; Stefani A; Barzon L; Sturniolo GC; Palù G; Castagliuolo I
Am J Physiol Gastrointest Liver Physiol; 2005 Apr; 288(4):G621-9. PubMed ID: 15764810
[TBL] [Abstract][Full Text] [Related]
35. Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.
Einsiedel J; Hübner H; Hervet M; Härterich S; Koschatzky S; Gmeiner P
Bioorg Med Chem Lett; 2008 Mar; 18(6):2013-8. PubMed ID: 18276136
[TBL] [Abstract][Full Text] [Related]
36. Binding chemistry and molecular heterogeneity of neurotensin binding protein(s)/receptor in adult chicken tissues.
Mitra SP
Indian J Biochem Biophys; 2013 Dec; 50(6):511-20. PubMed ID: 24772976
[TBL] [Abstract][Full Text] [Related]
37. Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications.
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Grosser OS; Osterkamp F; Pethe A; Reineke U; Smerling C; Amthauer H
J Nucl Med; 2016 Jul; 57(7):1120-3. PubMed ID: 26940767
[TBL] [Abstract][Full Text] [Related]
38. Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments.
Sparr C; Purkayastha N; Yoshinari T; Seebach D; Maschauer S; Prante O; Hübner H; Gmeiner P; Kolesinska B; Cescato R; Waser B; Reubi JC
Chem Biodivers; 2013 Dec; 10(12):2101-21. PubMed ID: 24327436
[TBL] [Abstract][Full Text] [Related]
39. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
40. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
